Marker Therapeutics (MRKR) Misses Q1 EPS by 2c

Marker Therapeutics (NASDAQ: MRKR) reported Q1 EPS of ($0.16), $0.02 worse than the analyst estimate of ($0.14).

"We had a productive first quarter supported by our recently completed financing, strengthening our overall cash position and enabling continued growth and expansion of our Multi-TAA pipeline," said Peter L. Hoang, President & CEO of Marker Therapeutics. "In addition, we continue to make strong progress on both the clinical and manufacturing fronts. In March, we dosed the first patient in the safety lead-in portion of our Phase 2 trial in post-transplant acute myeloid leukemia, or AML, and continue to activate clinical sites. In parallel, we continue to optimize the MT-401 cell therapy manufacturing process, which we believe could result in an increase in the number of T cells available for patient administration—among other benefits—as we prepare to operationalize our new in-house cGMP facility in the first half of the year."

For earnings history and earnings-related data on Marker Therapeutics (MRKR) click here.

You May Also Be Interested In

• Primoris cuts 2026 outlook on renewables cost overruns, COO exits
• Gil Issachar steps down as CTO at Firefly Neuroscience
• AXT appoints Tracy Liu to its board of directors